The relapsed or refractory diffuse large B-cell lymphoma market involves the treatment of lymphoma, which is a cancer that begins in lymphocytes – a type of white blood cell. It is an aggressive form of non-Hodgkin lymphoma. Relapse in DLBCL occurs when the cancer returns after initial treatment while refractory DLBCL is when the disease does not respond to initial treatment. Treatment options for patients suffering from this form of lymphoma include chemotherapy, immunotherapy, stem cell transplantation, targeted therapy and radiation therapy. The global relapsed or refractory diffuse large B-cell lymphoma market is witnessing significant growth due to the rising prevalence of cancer worldwide. According to GLOBOCAN 2018, around 882,450 new cases of NHL were registered globally.

The Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the relapsed or refractory diffuse large B-cell lymphoma market are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. These players are focusing on developing new and innovative treatment options to improve patient outcomes.

The growing demand for effective treatment is also driving the Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Size. With limited treatment options available and low survival rates, there is a need for improved drugs and therapies. Several pipeline drugs are under development which can potentially transform current treatment paradigms.

The market is also witnessing expansion in emerging economies due to the rising healthcare expenditure. Countries like India, China, Brazil, Mexico are allocating more funds for cancer care. This increases accessibility to advanced treatment modalities.

Market Drivers

The increasing incidence rate of lymphoma is a key growth driver for this market. According to the estimates of Lymphoma Coalition, over 82,000 new cases of lymphoma will be diagnosed in the United States in 2022. DLBCL accounts for around 30-40% of adult non-Hodgkin lymphoma cases. The growing geriatric population also contributes to the rising disease burden as age is a major risk factor. This ever-growing patient pool expands the potential market size for therapies.